PC 1 (explaining 52% of the variance between patients) was associated with the clinical Alzheimer’s disease CSF biomarkers beta-amyloid 42, phosphorylated tau 181, and total tau but not with Alzheimer’s disease-related neurodegeneration imaging markers, cognitive performance, or clinical diagnosis. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.